Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma
Oncolytics Biotech Inc. - Common Shares (ONCY)
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.oncolyticsbiotech.com
Company Research
Source: PR Newswire
SAN DIEGO and CALGARY, Alberta, Jan. 13, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) (TSX: ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided a recap of a Key Opinion Leader call sponsored by ROTH Capital Partners which was held on Thursday, January 9, 2020. The KOL call focused on recent data presented at the 61st American Society of Hematology Annual Meeting and Exposition and highlighted that carfilzomib promotes reovirus infection, that pelareorep upregulates PD-L1, and that delivery of additional data from ongoing pelareorep studies in multiple myeloma is planned for presentation at ASCO in June 2020.The KOL call was hosted and conducted by the equity research department at ROTH Capital and featured two of Oncolytics' multiple myeloma clinical investigators:Dr. Craig Hofmeister M.D., Winship Cancer Institute/Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlan
Show less
Read more
Impact Snapshot
Event Time:
ONCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCY alerts
High impacting Oncolytics Biotech Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ONCY
News
- Oncolytics Biotech Inc. (NASDAQ: ONCY) was upgraded by analysts at Raymond James to a "moderate buy" rating.MarketBeat
- Oncolytics Biotech Inc. (NASDAQ: ONCY) was downgraded by analysts at Leede Financial from a "strong-buy" rating to a "moderate buy" rating.MarketBeat
- Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Biotech Companies' Q3 Updates: Promising Cancer Treatments on the HorizonPR Newswire
- Biotech Companies' Q3 Updates: Promising Cancer Treatments on the HorizonPR Newswire
ONCY
Earnings
- 11/12/24 - Miss
ONCY
Sec Filings
- 11/12/24 - Form 6-K
- 11/12/24 - Form 6-K
- 11/12/24 - Form 6-K
- ONCY's page on the SEC website